公卫人

 找回密码
 立即注册

QQ登录

只需一步,快速开始

查看: 5628|回复: 3

[分享] Methods and Applications of Statistics in Clinical Trials, Volume 2 (2014)

[复制链接]
sampson2010 发表于 2015-5-27 17:09:33 | 显示全部楼层 |阅读模式

注册后推荐绑定QQ,之后方才可以使用下方的“用QQ帐号登录”。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
本帖最后由 sampson2010 于 2015-5-28 11:39 编辑 $ f7 b( M* v  j, X7 U
$ R/ W' J3 G* |0 V9 ]
1118304764.jpg , D$ w4 {, x: c; e

2 m4 ?7 c' b. v, cTitle: Methods and Applications of Statistics in Clinical Trials, Volume 2: Planning, Analysis, and Inferential Methods
1 M6 y( X: I! \0 VAuthor(s): N. Balakrishnan# O8 R" {2 M% `, A
Publisher: Wiley
2 w, U1 j1 H' O0 t! IYear: 2014       
7 O7 |  R% p! [/ [3 E/ xEdition: 13 E% f: _+ B! x( w
Language: English
6 ]" h, V7 E9 k0 U7 p8 r, BPages: 960
) K$ S6 d( ?" h/ d  h1 j7 KISBN: 1118304764, 9781118304761- Q5 }' k# E- X* \
Size: 63 MB (65940955 bytes)       
1 e& Y# E0 G9 u! _1 z, \5 KExtension: pdf

4 F+ |, n1 U: v8 _. R- |6 E" S! M' v- T. k! [( X- m2 I
6 E9 S, V, ~; y) n6 O
Description0 \8 O. K& O3 @& h4 n
) s' D; i; @$ P+ g) }7 M
Methods and Applications of Statistics in Clinical Trials, Volume 2: Planning, Analysis, and Inferential Methods includes updates of established literature from the Wiley Encyclopedia of Clinical Trials as well as original material based on the latest developments in clinical trials. Prepared by a leading expert, the second volume includes numerous contributions from current prominent experts in the field of medical research. In addition, the volume features:7 x0 Q- H" ^, m0 l+ l" _
% F9 f# s4 J/ \( x
• Multiple new articles exploring emerging topics, such as evaluation methods with threshold, empirical likelihood methods, nonparametric ROC analysis, over- and under-dispersed models, and multi-armed bandit problems
1 k4 X4 B2 }' |% j2 }! S4 G% k  {  u- b/ |, w* x( J( h8 D) j
• Up-to-date research on the Cox proportional hazard model, frailty models, trial reports, intrarater reliability, conditional power, and the kappa index" W. T+ q5 Q! e: E! F$ A; E3 U/ O

. O3 R' _5 k5 L( E$ ?$ C: ~/ w9 M; R• Key qualitative issues including cost-effectiveness analysis, publication bias, and regulatory issues, which are crucial to the planning and data management of clinical trials
* |; B/ J5 R- U  |; Q4 ~
( P. [7 f, G- ^0 V2 f7 H6 @* \: I9 K4 E# S* J) X
Table of Contents; v, Y2 e3 Y' ?. b) ?. P" ]: `+ e

! Z) O% ]* u7 ~" y# p1 L$ iContributors xix0 L. M) g1 e: F, I0 U" C
2 X* T# D( G' h
Preface xxiii& S9 y' u4 `( X6 a6 P
$ k! G7 Y* B/ h9 C& U5 x+ b. b
1 Analysis of Over- and Underdispersed Data 1
( l* T, @/ ]) L- q
. |9 ]* ?4 |* |4 G( H2 Analysis of Variance (ANOVA) 10
8 j: R+ u+ n# u( z. s! ~( Z* K: A9 D) y7 z5 T% x" o: Y( z" C5 |0 @
3 Assessment of Health-Related Quality of Life 26  x2 L! [- ?! A) B% ~4 F' q4 G
7 j- T& ^9 o( C
4 Bandit Processes and Response-Adaptive Clinical Trials: The Art of Exploration Versus Exploitation 40/ ^5 k1 }* Y& t1 l

9 ?7 c! t+ s0 U( u) P, Y5 Bayesian Dose-Finding Designs in Healthy Volunteers 51- M# E/ [2 }) m2 h! ^& M( H; Y8 m
- E* t0 h9 R" Z; O3 R. }6 s7 R
6 Bootstrap 62
& j8 b4 d. _; Z5 _
& t+ e, B8 ?( M/ C: R4 M8 U" T$ T7 Conditional Power in Clinical Trial Monitoring 102
# w9 U8 h3 g3 G6 G, m( z
/ k. h% \3 N! K  j- Z$ j+ N6 S8 Cost-Effectiveness Analysis 111( x  O& n% s2 M  l4 p  Q

+ u2 b2 ?6 a3 l3 o2 Q9 Cox-Type Proportional Hazards Models 126/ g! ^: P& q$ h( E2 R
. @3 m" T" W' H& \% x3 }
10 Empirical Likelihood Methods in Clinical Experiments 146/ L2 q8 X9 e  Z! D7 x
7 g- G/ K- g$ l& U+ g# `0 A
11 Frailty Models 166
- {, o5 M4 Y) \' P* R
" _) n" Y7 s5 j8 a3 ]4 V7 {' ^12 Futility Analysis 174
* L8 F$ W$ B) M8 `2 `) R
7 H$ H! U7 a1 m4 v13 Imaging Science in Medicine I: Overview 187" p, k4 g# K4 d) W' |
' }* x6 U& g4 u8 ?. a# X9 m, y
14 Imaging Science in Medicine, II: Basics of X-Ray Imaging 213! h. k' g  [) S. F5 g5 l
! W$ N" i; V% ^3 z0 N, v$ V$ X
15 Imaging Science in Medicine, III: Digital (21st Century) X-Ray Imaging 264
9 G) L( A% N: y+ `$ ]$ @  x4 w) L! q* i0 h. z, a
16 Intention-to-Treat Analysis 313! D7 z( P) [0 K7 z" j# ~

1 [( X& |4 g$ U7 U% K, c17 Interim Analyses 3237 E( b0 Z7 \/ h3 c2 E! u
& X5 x9 A2 h. a* j
18 Interrater Reliability 334% V5 \" q3 r& I7 J& {8 ?. @7 O

2 e4 E9 M( W! H19 Intrarater Reliability 340
  ], g: M8 K2 d% k: I4 i" b! F  l0 z$ |0 }. R! M" Z
20 Kaplan-Meier Plot 357
+ j  S) V, ]6 t% e6 S- B; F1 I2 Z; I0 s' E
21 Logistic Regression 365# l# @- ^8 e5 ~9 |) z: U$ R( ~8 g

" U# k4 ^2 N* E3 a/ r22 Metadata 380
& |* P6 v* W0 ?
8 R. {. u  D9 C23 Microarray 392
% Z# A5 L4 ~5 K8 a. j/ w8 z/ u* f8 \- Q0 }( X+ E# D
24 Multi-Armed Bandits, Gittins Index, and Its Calculation 416! _8 y' s: @1 G4 W( g

  e6 V# Y) a! V" @7 A  q! f25 Multiple Comparisons 436  ~7 R/ x/ S' J7 q; Y' _$ y
. c) I) e1 }( Z) x% m, L
26 Multiple Evaluators 4461 ]0 i' w* w" x5 n$ q
6 r# m! d! T* i* a  w* T
27 Noncompartmental Analysis 457
; |+ _. t" ^/ U& X" P* {9 [1 D) ^/ ?6 l: _
28 Nonparametric ROC Analysis for Diagnostic Trials 483
; b& F& I9 m% J8 {* G9 U: J' \- N# I6 L3 k- u" I
29 Optimal Biological Dose for Molecularly Targeted Therapies 496; a/ t3 u7 |0 E8 i. }* e

0 f3 A: s7 ^& X/ {' A/ a+ w30 Over- and Underdispersion Models 5066 C& x+ D) W9 r0 t( p" v9 y% ^

3 Z. O2 |) @8 ]) N, f/ _" l31 Permutation Tests in Clinical Trials 527
& F& a& w$ k, S2 P9 Y) t
( E) F$ q3 X5 K5 R" E! x2 Q' O) ^32 Pharmacoepidemiology, Overview 536
; v/ U7 b( h% i2 [2 m
1 L# z1 ?9 u0 F) N33 Population Pharmacokinetic and Pharmacodynamic Methods 551
. o0 R! V5 {8 x/ F; g" B  @
/ \8 k& H$ @: O. a; a34 Proportions: Inferences and Comparisons 5708 w5 E0 k1 _8 s& m6 R

* v& g6 H- t) B( i  U5 \% ^35 Publication Bias 595" t7 R6 ]. p/ J  ?2 g

& g. d. |4 L$ x/ `8 ^1 Q36 Quality of Life 608
# n- ]5 a8 Y, I" V5 n' s, L) R2 ?  X9 n) {# z
37 Relative Risk Modeing 6222 D5 c# U0 x6 V
! k. ?+ j7 a- a" k
38 Sample Size Considerations for Morbidity/Mortality Trials 633
* \) J: R! k0 Q% z  u# w
" x3 y0 u: i* u$ o39 Sample Size for Comparing Means 642
; p2 d; Y# r5 F6 N& |2 P9 ]8 x; z$ T5 i
40 Sample Size for Comparing Proportions 653
; G+ {* N8 t' N4 V. R
- R2 k/ w  T% W. |41 Sample Size for Comparing Time-to-Event Data 664' t+ L- ~. a6 h7 M

. K1 g9 w. G% t1 d42 Sample Size for Comparing Variabilities 672  ]5 l. m8 i2 ], Y" e7 G

' A2 i# L! L2 i$ N5 b43 Screening, Models of 6890 ]+ G* Z' ^6 L2 A  I8 a

; W+ @) W0 M( R) H7 s7 G1 q9 ^44 Screening Trials 7218 y- e/ ?2 S, c% F1 ^" [( d+ ]9 m

$ X# n8 k6 I) s7 H. b2 R" `45 Secondary Efficacy End Points 7312 w# Q( W: L0 N) C' g  S
$ x* G% g! |7 {0 v! ^9 p* m
46 Sensitivity, Specificity, and Receiver Operator Characteristic (ROC) Methods 740/ H# [9 ?# _2 \9 f  X

( Z0 y- m) l; ~7 |4 o, i9 P' @47 Software for Genetics/Genomics 7523 [4 t- r7 T1 J3 m7 f$ A, U

$ |  _8 Y& F& t6 Y3 D' l, k# ^48 Stability Study Designs 778
4 M  J0 R. m5 x/ S- y  [: {) A1 y6 ^4 a) m, d1 Z, R
49 Subgroup Analysis 793- V! q/ g6 |, c& e

( G( N7 B. D0 m. u) A. P$ ^2 v50 Survival Analysis, Overview 802' h/ I0 |- R) I% W# d( Z
$ e0 w5 i1 ]& Y- M
51 The FDA and Regulatory Issues 815
% O* m! M* b* b0 N
* Z9 b# Z8 |7 T8 [/ {; m/ {, r52 The Kappa Index 8368 S8 o) r: E+ E7 h

( z: N) Y0 E  D9 H3 c0 n* ?53 Treatment Interruption 846( A4 H( J0 X! Q
/ B7 ~3 j8 B5 u8 _/ }. J
54 Trial Reports: Improving Reporting, Minimizing Bias, and Producing Better Evidence-Based Practice 860
7 E) _/ y/ q1 Z
1 F0 e5 F# x3 ~4 p; d0 l55 U.S. Department of Veterans Affairs Cooperative Studies Program 876
$ f- Q& V  ~3 d) X& w3 K' x; T. U3 j4 r3 @# M
56 Women's Health Initiative: Statistical Aspects and Selected Early Results 901. `. c7 u6 G0 o  ]. V5 d

& t: a7 J  Y0 v* a57 World Health Organization (WHO): Global Health Situation 914
* L0 Z1 I) p: E0 T: v5 k) ^4 ~: r' l! Y* @* M, t- B
Index 925
2 B3 ~0 @% F" V$ m2 }! \& V3 N/ ]9 `0 \. y' |9 Y/ N& l, [% E1 E& y$ I
4 d4 N- m+ B" l; h' [
Author Information
4 w6 `, T. E  v1 ^7 U: Y% v* T$ D# k2 D8 z+ o$ V* n4 O
N. BALAKRISHNAN, PHD, is Professor in the Department of Mathematics and Statistics at McMaster University, Canada. He is the author of over twenty books and is the coeditor of Encyclopedia of Statistical Sciences, Second Edition, also published by Wiley.! U: P* \- Y2 }/ D+ u) n
! O) o' H  X6 n2 E- j  P

" P- k7 c  ~. G% i1 t2 s( {# H  g. J
PDF附件较大,请点击下载:2 d% f: I: T$ p+ M' i
Methods and Applications of Statistics in Clinical Trials, Volume 2: Planning, Analysis, and Inferential Methods6 B8 |9 i$ e( u2 V

8 L2 p$ }/ x4 Q# `+ t: E5 X. C- G; Q2 X
6 i, Q) K0 L2 ?
111830473X.jpg " ?" A. Z% h0 `
' M/ A4 f( l& q' |, @" r" `
Methods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs
& n  b7 [5 L4 s+ e2 a/ h7 W- A. m* c! E6 z/ I( b. _( S1 B. r
~~COMMING SOON~~6 h, P3 _/ ]6 M* Q) F6 S1 e- f' T
% [# a9 D7 ]! [9 A8 O2 n$ s

本帖被以下淘专辑推荐:

renm 发表于 2015-6-29 14:56:50 | 显示全部楼层
楼主强大!太谢谢啦!
回复

使用道具 举报

chf521chf521 发表于 2015-8-21 21:16:03 | 显示全部楼层
感谢,感谢,必须学习
回复

使用道具 举报

hprxq 发表于 2016-4-17 19:55:56 | 显示全部楼层
谢谢了,下载了
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

手机版|会员|至尊|接种|公卫人 ( 沪ICP备06060850号-3 )

GMT+8, 2024-6-11 11:19 , Processed in 0.180042 second(s), 8 queries , Gzip On, MemCached On.

Powered by Discuz! X3.4

© 2001-2023 Discuz! Team.

快速回复 返回顶部 返回列表